Skip to content
OpenCapital
Get started

Biogen BIIB Reportable Segment — Total Revenue

Similar metrics at other companies

Crinetics Pharmaceuticals logo
CRNXReportable Segment — Total Revenue
$10.73M+2,873%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Total Revenue
$127.2M+55.6%
Ardelyx logo
ARDXReportable Segment — Total revenues
$94.47M+27.5%
Arcus Biosciences logo
RCUSReportable segment — Total revenues
$17M-39.3%
Supernus Pharmaceuticals logo
SUPNReportable Segment — Total revenues
$207.71M+38.6%
BioCryst Pharmaceuticals logo
BCRXReportable Segment — Total revenues
$156.41M+7.5%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M—
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%—
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's reportable segment — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's reportable segment — total revenue?
Biogen (BIIB) reported reportable segment — total revenue of $2.48B in Q1 2026.
How has Biogen's reportable segment — total revenue changed year-over-year?
Biogen's reportable segment — total revenue increased by 1.9% year-over-year, from $2.43B to $2.48B.
What is the long-term trend for Biogen's reportable segment — total revenue?
Over 3 years (2022 to 2025), Biogen's reportable segment — total revenue has grown at a -0.9% compound annual growth rate (CAGR), from $10.17B to $9.89B.
What does reportable segment — total revenue mean?
This represents the total gross income generated by the primary business segment through the sale of pharmaceutical products and collaborative arrangements. It serves as the top-line indicator of market demand and commercial success for the company's core therapeutic portfolio. Tracking this metric helps assess the segment's ability to maintain market share in competitive therapeutic areas.